Group 1: Acquisition Details - BioMarin Pharmaceutical (BMRN) has entered into a definitive agreement to acquire Inozyme Pharma (INZY) for $4.00 per share, totaling nearly $270 million [1] - The acquisition is expected to close in the third quarter of 2025, following approval from the boards of both companies [1] Group 2: Strategic Fit and Pipeline Expansion - The acquisition will add Inozyme's lead asset, INZ-701, to BioMarin's pipeline, which is an investigational enzyme replacement therapy for ENPP1 deficiency, a rare genetic disorder [2][3] - INZ-701 is currently in a pivotal late-stage study, with interim results expected in early 2026 and potential regulatory approval in 2027 [3] Group 3: Market Impact and Stock Performance - Following the acquisition announcement, shares of Inozyme surged by 178%, while BioMarin's shares gained about 2% [5] - Year-to-date, BioMarin's shares have decreased by 10%, whereas Inozyme's shares have increased by 43% [5] Group 4: Benefits of the Acquisition - The deal is seen as a strategic fit for BioMarin, which already markets five first-in-disease enzyme therapies, thus expanding its Enzyme Therapies portfolio and diversifying revenue streams [6] - Inozyme benefits from the acquisition as it lacks the commercial infrastructure to bring a drug to market, an area where BioMarin is well established [8] Group 5: Financial Guidance - BioMarin has reaffirmed its full-year 2025 sales guidance of $3.1-$3.2 billion and adjusted EPS guidance of $4.20-$4.40 [8]

BioMarin Pharmaceutical (BMRN) reported first-quarter 2025 adjusted earnings per share of $1.13, which beat the Zacks Consensus Estimate of 94 cents. Quarterly earnings rose 59% year over year, driven by higher product sales and lower operating expenses.Total revenues were $745 million, which rose 15% year over year on a reported basis and 17% on a constant-currency basis. The top line beat the Zacks Consensus Estimate of $737 million. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar) ...

BioMarin Pharmaceutical (BMRN) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good day, everyone, and welcome to the BioMarin Pharmaceutical First Quarter twenty twenty five Conference Call. Just a reminder that this conference is being recorded. I would now like to hand things over to Ms. Tracy McCarty. Please go ahead, ma'am. Speaker1 Thank you, operator. To remind you, this non confidential presentation contains forward looking statements about the business prospects of BioMarin Pharmaceutical I ...

BioMarin Pharmaceutical (BMRN) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Traci McCarty - Group Vice President of Investor RelationsAlexander Hardy - President and Chief Executive OfficerBrian Mueller - CFO & EVPCristin Hubbard - Executive VP & Chief Commercial OfficerGreg Friberg - Executive Vice President, Chief Research & Development OfficerPhilip Nadeau - MD, Health Care – BiotechnologyTommie Reerink - Biotech Equity Research AssociateJenny Gonzalez-Armenta - Equity Research Ass ...